Capmatinib (Tabrecta): A Patient Guide for MET-Mutant Lung Cancer
Capmatinib targets advanced lung cancer with MET exon 14 skipping.
KESHAV
معلومات عن الادوية ودواعي الاستعمال والجرعات والسلامة مرتبطة بالمنتجات المتاحة حاليا.
Capmatinib targets advanced lung cancer with MET exon 14 skipping.
This is a landmark decision that will improve treatment options for children who have low and high-grade gliomas with a BRAF V600E mutation.
Oral tumors are relatively common in dogs, and canine oral squamous cell carcinoma (COSCC) is the most prevalent oral malignancy of epithelial origin.
Combination therapy with dabrafenib and trametinib has been shown to improve response and survival outcomes in patients with BRAF V600E-mutated non–small cell lung cancer (NSCLC).